Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Common stock purchase or sale:
| Transaction Date | Reported DateTime | Company | Symbol | Insider Relationship | Shares Traded | Average Price | Total Amount | Shares Owned | Filing |
| 2024-04-22 Sale | 2024-04-24 5:50 pm | GENELUX Corp | GNLX | Szalay Aladar 10% Owner | 44,395 | $3.506 | $155,647 | 4,069,490 (Indirect) | View |
| 2024-04-16 Sale | 2024-04-18 5:00 pm | GENELUX Corp | GNLX | Szalay Aladar 10% Owner | 71,420 | $3.5876 | $256,227 | 4,113,885 (Indirect) | View |
| 2023-12-15 Sale | 2023-12-18 4:15 pm | GENELUX Corp | GNLX | Yu Yong VP, Clinical Trial Operations | 32,535 | $13.16 | $428,180 | 0 (Direct) | View |
| 2023-12-13 Sale | 2023-12-14 8:59 pm | GENELUX Corp | GNLX | Tyree James L Director | 9,000 | $13.22 | $118,969 | 3,460 (Direct) | View |
| 2023-12-13 Sale | 2023-12-14 8:58 pm | GENELUX Corp | GNLX | Thomas John Director | 9,000 | $13.38 | $120,387 | 463,460 (Direct) | View |
| 2023-12-07 Sale | 2023-12-08 5:57 pm | GENELUX Corp | GNLX | Yu Yong VP, Clinical Trial Operations | 36,800 | $11.85 | $435,995 | 32,535 (Direct) | View |
| 2023-11-21 Sale | 2023-11-22 4:15 pm | GENELUX Corp | GNLX | Yu Yong VP, Clinical Trial Operations | 18,665 | $10.26 | $191,555 | 69,335 (Direct) | View |
| 2023-11-17 Sale | 2023-11-21 4:15 pm | GENELUX Corp | GNLX | Yu Yong VP, Clinical Trial Operations | 18,135 | $11.6 | $210,431 | 88,000 (Direct) | View |
| 2023-10-25 Sale | 2023-10-26 5:07 pm | GENELUX Corp | GNLX | Szalay Aladar 10% Owner | 5,704 | $19.4 | $110,638 | 4,185,305 (Indirect) | View |
| 2023-10-23 Sale | 2023-10-25 4:51 pm | GENELUX Corp | GNLX | Szalay Aladar 10% Owner | 49,987 | $19.97 | $998,365 | 4,191,009 (Indirect) | View |
| 2023-10-24 Sale | 2023-10-25 4:15 pm | GENELUX Corp | GNLX | Yu Yong VP, Clinical Trial Operations | 5,200 | $19.11 | $99,351 | 313,788 (Direct) | View |
| 2023-10-16 Sale | 2023-10-16 6:39 pm | GENELUX Corp | GNLX | Thomas John Director | 3,333 | $20.71 | $69,038 | 472,460 (Direct) | View |
| 2023-10-10 Sale | 2023-10-11 4:10 pm | GENELUX Corp | GNLX | Yu Yong VP, Clinical Trial Operations | 5,200 | $22.01 | $114,462 | 318,988 (Direct) | View |
| 2023-10-05 Sale | 2023-10-10 4:49 pm | GENELUX Corp | GNLX | Szalay Aladar 10% Owner | 14,251 | $24.93 | $355,229 | 4,240,996 (Indirect) | View |
| 2023-10-03 Sale | 2023-10-04 6:43 pm | GENELUX Corp | GNLX | Szalay Aladar 10% Owner | 75,690 | $25.49 | $1,929,225 | 4,255,247 (Indirect) | View |
| 2023-09-27 Sale | 2023-09-29 4:34 pm | GENELUX Corp | GNLX | Szalay Aladar 10% Owner | 13,546 | $24.41 | $330,669 | 4,330,937 (Indirect) | View |
| 2023-09-25 Sale | 2023-09-27 4:33 pm | GENELUX Corp | GNLX | Szalay Aladar 10% Owner | 42,263 | $24.38 | $1,030,181 | 4,344,483 (Indirect) | View |
| 2023-09-26 Sale | 2023-09-27 4:10 pm | GENELUX Corp | GNLX | Yu Yong VP, Clinical Trial Operations | 5,200 | $23.56 | $122,528 | 324,188 (Direct) | View |
| 2023-09-21 Sale | 2023-09-25 6:30 pm | GENELUX Corp | GNLX | Szalay Aladar 10% Owner | 16,591 | $27.85 | $462,001 | 4,386,746 (Indirect) | View |
| 2023-09-20 Sale | 2023-09-21 4:35 pm | GENELUX Corp | GNLX | Yu Yong VP, Clinical Trial Operations | 6,000 | $27.96 | $167,786 | 329,388 (Direct) | View |
| 2023-09-20 Sale | 2023-09-21 4:30 pm | GENELUX Corp | GNLX | Ryder Sean General Counsel | 10,000 | $30 | $300,000 | 140,572 (Direct) | View |
| 2023-09-18 Sale | 2023-09-20 4:48 pm | GENELUX Corp | GNLX | Szalay Aladar 10% Owner | 62,459 | $24.92 | $1,556,591 | 4,403,337 (Indirect Direct) | View |
| 2023-09-15 Sale | 2023-09-18 8:13 pm | GENELUX Corp | GNLX | Yu Yong VP, Clinical Trial Operations | 10,400 | $21.89 | $227,630 | 335,388 (Direct) | View |
| 2023-09-15 Sale | 2023-09-18 8:12 pm | GENELUX Corp | GNLX | Thomas John Director | 6,667 | $23.45 | $156,313 | 475,793 (Direct) | View |
| 2023-09-13 Sale | 2023-09-15 8:06 pm | GENELUX Corp | GNLX | Yu Yong VP, Clinical Trial Operations | 29,800 | $21.14 | $629,927 | 106,135 (Direct) | View |
| 2023-09-13 Sale | 2023-09-15 4:19 pm | GENELUX Corp | GNLX | Szalay Aladar 10% Owner | 44,308 | $21.8 | $965,899 | 4,465,796 (Indirect Direct) | View |
| 2023-09-13 Sale | 2023-09-14 8:18 pm | GENELUX Corp | GNLX | Smither John W Director | 900 | $20.78 | $18,702 | 6,920 (Direct) | View |
| 2023-09-11 Sale | 2023-09-13 7:04 pm | GENELUX Corp | GNLX | Szalay Aladar 10% Owner | 52,616 | $22.23 | $1,169,868 | 4,510,104 (Indirect Direct) | View |
Stock options: Exercise, Award, Grant, Conversion
| Transaction Date | Reported DateTime | Exercisable Expiration | Company | Symnbol | Insider Relationship | Shares Traded | Conversion Price | Shares Owned | Filing |
| 2023-10-24 Exercise | 2023-10-25 4:15 pm | N/A N/A | GENELUX Corp | GNLX | Yu Yong VP, Clinical Trial Operations | 5,200 | $6 | 313,788 (Direct) | View |
| 2023-10-24 Exercise | 2023-10-25 4:15 pm | N/A 2029-09-20 | GENELUX Corp | GNLX | Yu Yong VP, Clinical Trial Operations | 5,200 | $0 | 313,788 (Direct) | View |
| 2023-10-10 Exercise | 2023-10-11 4:10 pm | N/A N/A | GENELUX Corp | GNLX | Yu Yong VP, Clinical Trial Operations | 5,200 | $6 | 318,988 (Direct) | View |
| 2023-10-10 Exercise | 2023-10-11 4:10 pm | N/A 2029-09-20 | GENELUX Corp | GNLX | Yu Yong VP, Clinical Trial Operations | 5,200 | $0 | 318,988 (Direct) | View |
| 2023-10-02 Option Award | 2023-10-04 4:10 pm | N/A 2033-10-01 | GENELUX Corp | GNLX | Jewett Caroline Head of Quality | 22,000 | $0 | 22,000 (Direct) | View |
| 2023-09-26 Exercise | 2023-09-27 4:10 pm | N/A N/A | GENELUX Corp | GNLX | Yu Yong VP, Clinical Trial Operations | 5,200 | $6 | 324,188 (Direct) | View |
| 2023-09-26 Exercise | 2023-09-27 4:10 pm | N/A 2029-09-20 | GENELUX Corp | GNLX | Yu Yong VP, Clinical Trial Operations | 5,200 | $0 | 324,188 (Direct) | View |
| 2023-09-20 Exercise | 2023-09-21 4:35 pm | N/A N/A | GENELUX Corp | GNLX | Yu Yong VP, Clinical Trial Operations | 6,000 | $6 | 329,388 (Direct) | View |
| 2023-09-20 Exercise | 2023-09-21 4:35 pm | N/A 2029-09-20 | GENELUX Corp | GNLX | Yu Yong VP, Clinical Trial Operations | 6,000 | $0 | 329,388 (Direct) | View |
| 2023-09-20 Exercise | 2023-09-21 4:30 pm | N/A N/A | GENELUX Corp | GNLX | Ryder Sean General Counsel | 10,000 | $6 | 140,572 (Direct) | View |
| 2023-09-20 Exercise | 2023-09-21 4:30 pm | N/A 2031-10-03 | GENELUX Corp | GNLX | Ryder Sean General Counsel | 10,000 | $0 | 140,572 (Direct) | View |
| 2023-09-15 Exercise | 2023-09-18 8:13 pm | N/A N/A | GENELUX Corp | GNLX | Yu Yong VP, Clinical Trial Operations | 10,400 | $6 | 335,388 (Direct) | View |
| 2023-09-15 Exercise | 2023-09-18 8:13 pm | N/A 2029-09-20 | GENELUX Corp | GNLX | Yu Yong VP, Clinical Trial Operations | 10,400 | $0 | 335,388 (Direct) | View |
| 2023-09-11 Option Award | 2023-09-15 8:06 pm | N/A 2033-09-10 | GENELUX Corp | GNLX | Zindrick Thomas President and CEO | 250,000 | $0 | 250,000 (Direct) | View |
| 2023-09-11 Option Award | 2023-09-13 8:18 pm | N/A 2033-09-10 | GENELUX Corp | GNLX | Mirabelli Mary Director | 7,857 | $0 | 8,857 (Direct) | View |
| 2023-09-11 Option Award | 2023-09-13 8:16 pm | N/A 2033-09-10 | GENELUX Corp | GNLX | Tyree James L Director | 7,857 | $0 | 16,857 (Direct) | View |
| 2023-09-11 Option Award | 2023-09-13 8:15 pm | N/A 2033-09-10 | GENELUX Corp | GNLX | Thomas John Director | 7,857 | $0 | 486,857 (Direct) | View |
| 2023-09-11 Option Award | 2023-09-13 8:14 pm | N/A 2033-09-10 | GENELUX Corp | GNLX | Smither John W Director | 15,367 | $0 | 16,267 (Direct) | View |
Ownership | 2023-09-13 8:13 pm | N/A N/A | GENELUX Corp | GNLX | Smither John W Director | 0 | $0 | 900 (Direct) | View |
| 2023-09-11 Option Award | 2023-09-12 4:26 pm | N/A 2033-09-10 | GENELUX Corp | GNLX | Ryder Sean General Counsel | 40,000 | $0 | 40,000 (Direct) | View |
| 2023-09-11 Option Award | 2023-09-12 4:25 pm | N/A 2033-09-10 | GENELUX Corp | GNLX | Samuelson Doug Vice President, Finance | 40,000 | $0 | 40,000 (Direct) | View |
| 2023-09-11 Option Award | 2023-09-12 4:24 pm | N/A 2033-09-10 | GENELUX Corp | GNLX | Yu Yong VP, Clinical Trial Operations | 65,000 | $0 | 65,000 (Direct) | View |
| 2023-09-11 Option Award | 2023-09-12 4:23 pm | N/A 2033-09-10 | GENELUX Corp | GNLX | Cappello Joseph VP, Pharmaceutical Development | 65,000 | $0 | 65,000 (Direct) | View |
| 2023-09-11 Option Award | 2023-09-12 4:22 pm | N/A 2033-09-10 | GENELUX Corp | GNLX | Smalling Ralph Head of Regulatory | 64,000 | $0 | 66,065 (Direct) | View |